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Abstract 
Background: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to 
improve the quality of care and promote the independent research in sarcomas. The increased regulatory require-
ments, the chance to increase the number of trials with other cooperative groups and an interest from pharma-
ceutical companies in supporting independent research, generated the need of an internal service for research 
management.
Methods and results: In 2010, ISG implemented in its organization a Clinical Trial Unit (CTU). The CTU was appointed 
to fully manage Clinical Trial Operations, to guarantee regulation compliance and provide a central support to the 
investigators, fostering a collaboration both at national and international level. In 2016 ISG promoted 25 studies in 
about 120 centers, with a fivefold increase in the last 5 years: 68% were interventional and 32% observational. Nine 
of the 17 interventional studies (52%) were supported by pharmaceutical companies, while 4 (24%) were funded by 
European Commission within specific projects on sarcomas and 4 (24%) were supported by the ISG itself.
Conclusion: The contribution of ISG researchers to the international community was striking from the earliest years 
of the ISG creation. The challenges of the regulatory clinical research scenario, which imposes solid and hard-fast 
methodology with deep knowledge and expertise, highlighted the need to identify qualified and dedicated experts 
able to run and follow the multifaceted aspects of trials. Our analysis demonstrated how this model has led to a 
growth in competitiveness of the group. The collaboration between clinicians and CTU made possible to support 
the research with high scientific and ethical standards and to increase the number of trials, sites and overall enrolled 
patients. The reduced time for approvals, the continuous support to sites, the increased speed in data collection and 
analysis make the ISG research attractive for pharmaceutical industries, despite the problems that have character-
ized the independent research in the last years. The ability to fully manage and oversight Clinical Operations and the 
high quality of delivered services, have led the ISG to be recognized as a reliable partner and coordinator within the 
international sarcoma networks.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Sarcomas are rare tumors of mesenchymal origin, 
accounting for nearly 21 and <1% of all pediatric and 
adult solid malignant tumors, respectively [1].
Clinical trial research in disease with a low incidence 
like sarcomas (<6 per 100,000 people per year) is crucial 
to guarantee to the affected population the opportunity 
to access new treatments and benefit from medical and 
scientific progresses [2, 3].
However, in rare diseases, clinical research is chal-
lenging: few clinical trials are available for these popu-
lations and patients encounter difficulties in accessing 
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specialized centers where the most innovative clinical tri-
als are run [4].
In addition, conventional clinical trial designs are not 
always applicable and the statistical design needs to be 
modulated in order to make the studies feasible also in 
small populations [5–9].
The management of sarcomas poses several problems 
and the need for reference centers to share their expe-
riences let to the creation of networks and consortia of 
specialists [10, 11].
From the late eighties the Italian reference centers 
specialized in sarcoma treatment, began to collaborate 
within some national research programs and participated 
to the development of investigator-initiated clinical trials 
[12, 13].
From this experience, they felt the need to share their 
expertise and joint together in an Italian research net-
work aimed to improve the academic research and 
committed to try to provide answers to unmet clinical 
questions, especially in the extremely rare sarcomas, or 
for peculiar sarcoma subtypes.
Thus in 1997, the Italian Sarcoma Group (ISG) was 
founded and, legally recognized as a scientific independ-
ent non-profit association in 2002, begun to promote 
independent clinical trials.
From the time the European Clinical Trials Direc-
tive 2001/20/CE [14] was fully adopted in Italy, at the 
end of 2007, its effects resulted in an increased in strict-
ness and complexity of trial activities and trial oversight 
procedures.
This regulation, the chance to increase the number of 
trials conducted within international consortia [15, 16] 
and a greater interest of pharmaceutical companies in 
supporting independent research, imposed the need to 
introduce in the ISG organization, a Clinical Trial Unit 
(CTU) exclusively dedicated to Clinical Trial Operations 
to serve as an operative focal point for national and col-
laborative trials in sarcomas.
Methods
Development of the Clinical Trial Unit
The proposal to implement a CTU was presented to the 
ISG Directive Executive Board in 2009 that granted its 
approval for the initial financial support.
The source of funds was covered by the fundrais-
ing activities of the group and by the internal overheads 
derived from previous supported studies The main CTU 
office was established at central level and, under the cen-
tral coordination, two satellites offices were introduced in 
other institutions.
The assigned mission to CTU was to promote high 
quality standard of the group promoted research, to 
guarantee the compliance with regulation, to provide 
central support to participating sites, to facilitate collab-
oration between them and to collaborate with the other 
European sarcoma cooperative groups, involved in com-
mon international studies.
Analysis
The impact of the CTU in ISG clinical research was 
assessed by comparing the number of clinical studies, the 
number of activated sites and of enrolled patients, the 
performance in data collection and the funds received to 
conduct the trials, in the time period from 2010 to the 
3rd quarter of 2016.
The analysis included data of interventional, transla-
tional and observational studies as well as the educational 
activity promoted by the CTU.
Results
The first step toward the CTU creation was to imple-
ment the Clinical Operation (ClinOp) services, within 
the ISG secretariat by part-time personnel with a previ-
ous specific expertise in the management of clinical trials 
in sarcomas.
Among the first services offered were those related to 
study monitoring (site initiation, monitoring, and close-
out visits) and to the development of specific Clinical 
Trial Monitoring Standard Operative Procedures, (CTM-
SOPs) to be applied to all the ISG clinical trials, in full 
compliance with the regulatory requirements.
From 2010 to 2012 the number of interventional clini-
cal trials and centers completely managed by ISG ClinOp, 
increased respectively of 75% (from 4 to 7 studies) and 
158% (from 26 to 67 activated sites).
As consequence to these first positive results an inter-
nal budget analysis was performed.
The recorded increase of funds (+48%) allowed ISG to 
introduce a fully independent CTU, able to cover its own 
expenses with their services.
CTU was then formally recognized by ISG and, from 
mid-2013, the ISG ClinOp were no longer part of the sec-
retariat services, but started to be delivered by the inde-
pendent CTU.
Responsibility of the CTU is to oversight the trial man-
agement for interventional and observational multi-sites 
clinical studies where ISG is sponsor or national coordi-
nator within international consortia networks programs.
As reporte d in Table 1, the services offered by CTU to 
the group are focused on 5 main domains: scientific sup-
port, project management, safety and regulatory manage-
ment, educational and CTU administrative management.
From the beginning of 2014 the CTU also introduced 
an independent pharmacovigilance office and developed 
Standard Operative Procedures (SOP) to cover all the 
safety related activities.
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When the first ISG ClinOp services were implemented 
in 2010, 6 studies (4 interventional and 2 observational) 
were ongoing and were mainly managed by the coordi-
nating investigators.
The trials promoted by ISG or in collaboration with 
other international sarcoma networks in mid-2016 were 
25: 17 (68%) interventional and 8 (32%) observational 
(Table 2).
52% (n  =  9) of the interventional have financial sup-
port from pharmaceutical companies, while 24% (n = 4) 
received funds within sarcoma European Commis-
sion projects and 24% (n  =  4) are supported by ISG 
itself (Table  3). Taking into account only the interven-
tional studies, whereof regulatory requirements impose 
stringent quality standards, a great improvement in the 
number of managed clinical sites and patients has been 
Table 1 Clinical Operation Services offered by ISG CTU
Scientific support
Protocol development
 Support to the coordinator physician within the study board, for the implementation of the ethical aspects and safety requirements of research
Study report, publication and result dissemination
 Support to the final study report, publication submission and dissemination of the study results
Study project management
Study budget plan and budget negotiation
 Evaluation of study costs, budget plan development and budget negotiation with pharma companies supporters of the independent research or 
with partners within consortium projects
Study feasibility
 Support to sites selection through site feasibility development within the study board
Regulatory documentation
 Preparation of the regulatory documents, preparation and maintenance of the study binders in accordance with Good Clinical Practices and ISG Clini-
cal Trial Standard Operating Procedure (SOP)
Regulatory submission
 Submission to the Competent Authorities and Independent Review Boards (IRB) of the regulatory (protocols, patient’s information sheet and informed 
consents, Investigational Product information, safety information and all the others applicable documents)
 Support activity in the preparation of the submission package for extra-Italian submission within international studies coordinated by ISG
Investigational Product (IP) activities
 Management of the IP from labeling (if required) to supply and resupply activities
Database development
 Support to the Case Report Form design
Investigators meetings
 Support in the organization of the Investigators Meetings and logistics
Monitoring activities
 Management and conduction, either remote and onsite, of the site activation, monitoring and close-out visits
Coordination of centralized activities
 Development of procedures for centralized activities (samples management in case of centralized biological material analysis, centralized imaging 
review management)
Communication with the sites
Study state of art continuous monitoring
Regulatory and safety management
 Safety regulatory activities conducted by the Pharmacovigilance Office
 Communication of safety information (SUSAR, SAE line listing) to Competent Authorities and sites
 Eudravigilance reporting activities
Educational
 Protocol training activities
 Training on GCP, regulatory and clinical operation
Administrative
 Protocol budget plan
 Site contract negotiation
 External services contract negotiation
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recorded from 2010 to mid-2016, bringing the CTU to 
manage from 25 to 119 sites (+376%) and more than 800 
active patients (+543%) with an mean increase, respec-
tively, of 31 and 38% per year (Table 4).
Also a speed up in the time of ethical approval and in 
first patient enrollment have been recorded: a reduced 
mean time for approval of 4 months (and of 2 months for 
the First Patient First Visit).
During its 6 years of activity the high quality standard 
of clinical trial management, together with the capabil-
ity of providing a comprehensive service for the ClinOp, 
brought the Italian Sarcoma Group to increase its collab-
orations within international cooperative groups (from 0 
to 9 cooperative studies).
The services offered by the CTU had also impact on the 
supported research activity, with a more than sevenfold 
increase of funds from 2010 to 2016, and a mean number 
of new contracts for supported trials, in the last 3 years, 
of 3.3 (Table 5).
On the other hand, the increase of research manage-
ment activities brought the need to potentiate the CTU 
personnel that, in mid-2016 account for 2 full time units 
and 5 partially dedicated units from satellites.
The key effort of the CTU in facilitating the collabora-
tion within consortia trials led ISG to join as partner or 
leader in several European consortia studies.
This also permitted a direct collaborations with other 
European sarcoma CTU through the sharing of SOP and 
of the best ClinOp practices.
All the results of the ISG clinical studies, oversight by 
the CTU, are object of international meeting presen-
tations and are published in the most important peer 
reviewed oncology journals.
The CTU is also committed in promoting educational 
and training activities, like periodic courses, addressed 
not only to Clinical Research Coordinators (CRC) and 
to the Investigators interested in clinical trial regula-
tion and research methodology. As part of the educa-
tional mission of the CTU, from 2013 ISG introduced 
in its annual meeting, a parallel section dedicated to 
clinical trial coordination where regulatory and break-
ing news from trial regulation and methodology are 
presented.
The personnel of the CTU also collaborate with 
national groups in research methodology education and 
is involved in research in the field of clinical trial regula-
tions [17, 18].
Discussion
In the last decade, ISG research network played a key role 
in the development of independent research in the sar-
coma field, in Italy, promoting more than 30 clinical trials 
and managing over 100 sites with more than 800 patients. 
The number of clinical trials increased steadily from the 
Table 2 Number and type of studies managed by the CTU
Year Interventional Observational
2010 4 (71%) 2 (29%)
2011 7 (78%) 2 (22%)
2012 7 (78%) 2 (22%)
2013 7 (78%) 2 (22%)
2014 12 (66%) 6 (34%)
2015 13 (68%) 6 (32%)
2016 17 (68%) 8 (32%)
Table 3 Funding sources for interventional studies
Year Supported by pharma 
companies
Supported within EC 
sarcomas’ projects
Supported 
by ISG
2010 2/4 (50%) 0 (0%) 2 (50%)
2011 4/7 (57%) 1 (14%) 2 (29%)
2012 3/7 (43%) 1 (14%) 3 (43%)
2013 3/7 (43%) 1 (14%) 3 (43%)
2014 6/12 (50%) 3 (25%) 3 (25%)
2015 6/13 (46%) 4 (31%) 3 (23%)
2016 9/17 (52%) 4 (24%) 4 (24%)
Table 4 Number of interventional CT studies, sites and patients managed by the CTU
NE not evaluated
Year Nr of ongoing interventional 
trials
Nr. of sites New sites/year Nr. of active  
patients
New active 
patients/year
2010 4 26 NE 127 NE
2011 7 48 23 207 80
2012 7 67 18 323 116
2013 7 74 8 503 180
2014 12 91 17 601 98
2015 13 107 16 797 196
2016 17 119 12 816 19
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CTU introduction, and the possibility to independently 
manage them, contributed to increase the number of 
consortia and pharmaceutical supported research.
This led to a significant annual income increase that 
resulted in a self-financing system where the CTU is able 
to provide to its own maintenance.
Reduced time for regulatory approvals, immediate and 
continuous support to sites, and speed up in data collec-
tion and analysis, are making the ISG clinical research 
attractive for pharmaceutical industries, despite the fact 
that independent research in this field has been extremely 
challenging in the last years.
Finally, the feedback received from the ISG investiga-
tors about the support provided by CTU is extremely 
positive and contributes to increase the network collabo-
ration and involvement, not only in terms of recruitment 
and data quality, but also in terms of clinical trial coordi-
nation activities.
Conclusion
Contribution of ISG researchers to the international 
community was considered from the earliest years of ISG 
creation.
The regulatory trial scenario requires a more solid and 
hard-fast methodology with depth knowledge and exper-
tise. These challenges highlighted the need to identify 
expert and dedica ted professionals able to run, manage 
and follow the multifaceted aspects of innovative clinical 
trials.
The proactive collaboration between clinicians and 
CTU professionals made possible to support the increas-
ing research activity with high scientific and ethical 
standards.
The introduction of the CTU within the ISG organi-
zation represented an important a chievement in the 
group’s research activity, by facilitating its conduction.
This allows the group to be competitive and be recog-
nized as a reliable partner within the international sar-
coma networks and to lead the conduction of consortia 
clinical trials.
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